Morepen Laboratories Ltd.
Morepen Laboratories Ltd.
Delhi, India

COMPANY OVERVIEW

Company Album

Basic Information
Greetings from Morepen Laboratories Limited, India. Morepen Laboratories Limited as one of the preferred APIs & Intermediates manufacturers in the global pharma market for Innovator & Generic companies worldwide including highly regulated markets like US, Canada, Japan & Western Europe. Morepen is supported by a 40 members R&D team, which has 24 published process and polymorph patents to its credit for Loratadine, Desloratadine, Montelukast, Atorvastatin, Fexofenadine, etc. We invest in R&D and offer the product to our customers for licensing/contract manufacturing with required regulatory documents like Drug Master File both Open and Close parts (COS/ EDMFs) Method & Process Validations Non-Infringement patent statement. Morepen Laboratories Limited is the world s largest manufacturer of Loratadine, an antihistaminic drug, which is manufactured at our USFDA approved facility in Parwanoo, Himachal Pradesh. Our USFDA approved plant coupled with excellent documentation and customer service is our winning edge. Additionally, we have Montelukast, which is a key molecule for us and we have four process patents for this molecule in the regulated market. This product is also backed by the complete regulatory documentary requirement. The APIs which are commercially available are as below : Montelukast Sodium ( EDMF ) Loratadine ( USDMF, CEP) Desloratadine ( USDMF, EDMF ) Atorvastatin Calcium Amorphous ( USDMF, EDMF ) Atorvastatin Calcium Crystalline ( USDMF, EDMF ) Fexofenadine Hydrochloride ( EDMF ) Rosuvastatin Calcium ( Tech Pack ) Aliskiren Hemifumerate Prasugrel Valsartan Voglibose
  • Transactions
    -
Business type
Manufacturer
Country / Region
Delhi, India
Main ProductsTotal employees
Above 1000 People
Year established
1990
Certifications
-
Product Certifications
-
Patents
-
Trademarks
-
Main Markets

TRADE CAPABILITIES

Main Markets & Product(s)

Main markets
Total Revenue(%)
Main Product(s)
Verified
North America
9.09%
Eastern Europe
9.09%
Southeast Asia
9.09%
Africa
9.09%
Oceania
9.09%
Mid East
9.09%
Eastern Asia
9.09%
Western Europe
9.09%
Central America
9.09%
Northern Europe
9.09%
Southern Europe
9.09%
Verified